Biotech companies tend to have limited bandwidth and constrained resources to catch avoidable failure. Trials rarely fail at the end — they fail in the design.
Trials rarely fail at the end — they fail in the design. Flawed endpoints, underpowered studies, and poor patient selection can undermine success before Patient 1 is enrolled.
Site management breakdowns, data quality issues, and regulatory non-compliance destroy trials the science would have won.
At Stratavera, we identify and solve these issues before they become costly amendments, delays, or failed milestones.
Your embedded development team — senior pharma leadership, without the overhead.
Every protocol undergoes our 12-point clinical protocol inspection, then simulated trials to stress-test population, criteria, and endpoints before a single patient is enrolled.
The team that designs your trial also executes it. No re-briefing, no lost context, no waiting on a senior person to become available.
We function as your in-house clinical development organization — scientific, statistical, and operational leadership normally found only at large pharma.
Stratavera provides the scientific, statistical, and operational leadership your program needs — in one accountable team.
100+ combined years across GSK, J&J, Amgen, DURECT, and EpicentRx — a team that has already worked together, across multiple programs.
38+ years across GSK, ALZA, DURECT, EpicentRx. Led RRx-001 from lead optimization through Phase 3.
Full biostatistics spectrum worldwide — regulatory submissions and data management across 10+ therapeutic areas.
40+ years in clinical operations, regulatory, and quality leadership under active INDs.
Traditional CROs are optimized for volume, not speed. Senior decision-makers are on every call, protocols are optimized upfront, and there are no internal escalation chains slowing your program down.
All three founders have worked together across multiple programs. You're not betting on a team that might work — you're hiring one that already does.